Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEART-DAPA-MM trial of dapagliflozin for cardioprotection in newly diagnosed multiple myeloma undergoing autologous stem cell transplantation
2026-525418-67-00Phase 2Authorised
- Sponsor
- Institute of Hematology and Transfusion Medicine
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple myeloma (MM) comparing Forxiga cardioprotection arm with Placebo control arm (2 arms). Primary endpoint: Proportion of participants with at least one adjudicated major adverse cardiovascular event. Planned start Aug 2026; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2026-525418-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525418-67-00.